Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Dominic Pizzarella, Amanda Kofides, Xia Liu, John Hatcher, Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Hao Sun, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Sirano Dhe-Paganon, Steven Treon, Shirong Liu

Blood (2025) 146 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2025-7453

Published: 2025

Journal Articles

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey, Nickolas Tsakmaklis, Maria Luisa Guerrera, Xia Liu, Shirong Liu, Hao Sun, Alberto Guijosa, John Hatcher, Dominic Pizzarella, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2025-3544

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Shirong Liu, Xia Liu, Amanda Kofides, John Hatcher, Nickolas Tsakmaklis, Abigail Peachey, Dominic Pizzarella, Alberto Guijosa, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Steven Treon

Blood (2025) 146 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2025-2171

Published: 2025

Journal Articles

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

Xia Liu, Shirong Liu, Amanda Kofides, Dominic Pizzarella, Jinhua Wang, Sara Buhrlage, Nickolas Tsakmaklis, Abigail Peachey, Alberto Guijosa, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, John Hatcher, Steven Treon

Blood (2025) 146 (Supplement 1): 5324.

https://doi.org/10.1182/blood-2025-5324

Published: 2025

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andres Ramirez, Amanda Kofides, Abigail Peachey, Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 224.

https://doi.org/10.1182/blood-2025-224

Published: 2025

Journal Articles

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Xia Liu, MD, Jiaji G Chen, Manit Munshi, MS, Lian Xu, MS, Amanda Kofides, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Kirsten Meid, MPH, Andrew Keezer, BS, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2019) 134 (Supplement_1): 3778.

https://doi.org/10.1182/blood-2019-130885

Published: 2019

Journal Articles

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Guang Yang, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Amanda Kofides, Lian Xu, MS, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael Gray, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 394.

https://doi.org/10.1182/blood-2019-130636

Published: 2019

Journal Articles

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

Guang Yang, PhD, Jinhua Wang, PhD, Li Tan, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Lian Xu, MS, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Zachary R Hunter, PhD, Christopher Patterson, MAcc, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 40.

https://doi.org/10.1182/blood-2018-99-119171

Published: 2018

Journal Articles

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Manit Munshi, MS, Jiaji Chen, BS, Xia Liu, MD, Lian Xu, MS, Nickolas Tsakmaklis, BA, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Christopher Patterson, MAcc, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Zachary R Hunter, PhD, Jinhua Wang, PhD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2018) 132 (Supplement 1): 4116.

https://doi.org/10.1182/blood-2018-99-117372

Published: 2018

Journal Articles

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, MS, Xia Liu, MD, Christopher Patterson, Maria Luisa Guerrera, MD, Manit Munshi, MS, Guang Yang, PhD, Jiaji G Chen, Cristina Jimenez, PhD, Gloria G Chan, MS, Joshua Gustine, MPH, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Zachary R Hunter, PhD

Blood (2018) 132 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2018-99-119419

Published: 2018

Journal Articles

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Joshua Gustine, Kirsten Meid, MPH, Patricia Severns, NP, Toni Dubeau, NP, Nickolas Tsakmaklis, BA, Christopher Patterson, MAcc, Guang Yang, PhD, Xia Liu, MD, Maria Demos, BS, Amanda Kofides, BS, Jiaji Chen, BS, Manit Munshi, MS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Lian Xu

Blood (2017) 130 (Supplement 1): 5140.

https://doi.org/10.1182/blood.V130.Suppl_1.5140.5140

Published: 2017

Journal Articles

Characterization of Chromosome 6q Deletions in MYD88 Mutant and Wild-Type Waldenström's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 4984.

https://doi.org/10.1182/blood.V130.Suppl_1.4984.4984

Published: 2017

Journal Articles

Dysregulation of MYD88 Regulatory Isoforms in Waldenstrom's Macroglobulinemia

Amanda Kofides, BS, Maria Demos, BS, Nickolas Tsakmaklis, BA, Lian Xu, Xia Liu, MD, Guang Yang, PhD, Manit Munshi, MS, Jiaji Chen, BS, Christopher Patterson, MAcc, Maria Luisa Guerrera, MD, Jorge J. Castillo, MD, Steven P Treon, MDPhDFRCP, Zachary Hunter, PhD

Blood (2017) 130 (Supplement 1): 4967.

https://doi.org/10.1182/blood.V130.Suppl_1.4967.4967

Published: 2017

Journal Articles

BTK Cys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

Jiaji Chen, BS, Xia Liu, MD, Manit Munshi, MS, Lian Xu, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Zachary Hunter, PhD, Christopher Patterson, MAcc, Joshua Gustine, Jorge J. Castillo, MD, Steven P Treon, MDPhDFRCP, Guang Yang, PhD

Blood (2017) 130 (Supplement 1): 803.

https://doi.org/10.1182/blood.V130.Suppl_1.803.803

Published: 2017

Journal Articles

A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells

Guang Yang, PhD, John Hatcher, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji Chen, BS, Lian Xu, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Gloria Chan, MS, Zachary Hunter, PhD, Christopher Patterson, MAcc, Joshua Gustine, Jorge J. Castillo, MD, Nathanael Gray, PhD, Steven P Treon, MDPhDFRCP, Sara Buhrlage, PhD

Blood (2017) 130 (Supplement 1): 719.

https://doi.org/10.1182/blood.V130.Suppl_1.719.719

Published: 2017

Journal Articles

Differential Diagnosis of Suspected MYD88 Wild-Type Waldenstrom's Macroglobulinemia Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Steven P Treon, MDPhDFRCP, Zachary Hunter, PhD, Joshua Gustine, Kirsten Meid, MPH, Lian Xu, Xia Liu, MD, Guang Yang, PhD, Manit Munshi, MS, Robert Manning, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Maria Luisa Guerrera, MD, Jiaji Chen, BS, Gloria Chan, MS, Christopher Patterson, MAcc, Toni Dubeau, NP, Patricia Severns, NP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 4385.

https://doi.org/10.1182/blood.V130.Suppl_1.4385.4385

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas.

Novel mechanistic insights for IRAK1 and IRAK4 signaling provide a framework for the development of dual IRAK1 and IRAK4 protacs for MYD88 mutated lymphomas.

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

MYD88 Triggered SYK Activation Promotes BCR Cross-Talk, and Identifies SYK As a Novel Therapeutic Target of Mutated MYD88 Signaling

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Characterization of Chromosome 6q Deletions in MYD88 Mutant and Wild-Type Waldenström's Macroglobulinemia

Dysregulation of MYD88 Regulatory Isoforms in Waldenstrom's Macroglobulinemia

BTK Cys481Ser Mutation Drives Ibrutinib Resistance through ERK1/2 Hyperactivation, and Can Confer a Protective Effect on Bystander Waldenstrom's Macroglobulinemia and ABC DLBCL Cells through Paracrine Mediated Pro-Survival Signaling

A Novel, Highly Selective IRAK1 Inhibitor Jh-X-119-01 Shows Synergistic Tumor Cell Killing with Ibrutinib in MYD88 Mutated B-Cell Lymphoma Cells

Differential Diagnosis of Suspected MYD88 Wild-Type Waldenstrom's Macroglobulinemia Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only